Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Deals

GenScript Receives $213.8M Payment from LaNova for PD-1 Antibody License

Fineline Cube Jun 30, 2025

China-based GenScript Biotech Corporation (HKG: 1548) announced that it has received a payment of USD...

Company Drug

UCB’s Fenfluramine Shows Positive Results in Phase III GEMZ Study for CDKL5 Deficiency Disorder

Fineline Cube Jun 30, 2025

Belgium-based biopharma UCB (EBR: UCB) announced positive results from its Phase III GEMZ study, evaluating...

Company Deals

Sunshine Lake Pharma Lists on HKEX via Introduction Method

Fineline Cube Jun 30, 2025

China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board...

Company Deals

MGI Tech Partners with Italy’s Negedia to Advance Genomic Sequencing and Spatial Transcriptomics

Fineline Cube Jun 30, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. announced a collaboration with Italy’s Negedia to...

Policy / Regulatory

China Proposes Healthcare Security Law to Strengthen Medical Insurance System

Fineline Cube Jun 30, 2025

China’s National Healthcare Security Administration (NHSA) last week released the “Healthcare Security Law (draft proposal)”,...

Company Deals

QuantumPharm and Pfizer Expand Collaboration on Advanced Molecular Simulation Platform

Fineline Cube Jun 30, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its...

Company Deals

BlissBio Inc. Files for Hong Kong IPO to Advance Oncology-Focused ADC Pipeline

Fineline Cube Jun 30, 2025

Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with...

Policy / Regulatory

FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies

Fineline Cube Jun 30, 2025

The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...

Company Deals

ProFound Therapeutics and Novartis Forge Four-Year Partnership for Cardiovascular Drug Targets

Fineline Cube Jun 30, 2025

US-based ProFound Therapeutics announced a four-year partnership with Swiss giant Novartis (NYSE: NVS) to discover...

Company Deals

Diagens Biotech’s AI Imaging Platform iMedImage Makes Hong Kong IPO Debut

Fineline Cube Jun 30, 2025

China-based Hangzhou Diagens Biotechnology Co., Ltd. has filed for an initial public offering (IPO) with...

Company Drug

Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections

Fineline Cube Jun 30, 2025

US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s...

Company Drug

Gilead’s Lenacapavir Approved in Hainan for HIV-1 Pre-Exposure Prophylaxis

Fineline Cube Jun 30, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir,...

Company Deals

GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success

Fineline Cube Jun 30, 2025

China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the...

Company Deals

DK Medtech Partners with Mozarc Medical to Enhance Hemodialysis Access Solutions

Fineline Cube Jun 28, 2025

Suzhou-based DK Medical Technology Co. Ltd., a developer of vascular intervention balloon products, has entered...

Company Drug

ACIP Recommends MSD’s Enflonsia for Infants Under 8 Months to Prevent RSV

Fineline Cube Jun 27, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) revealed that the Advisory Committee...

Others

Viatris Announces Positive Results in VEGA-3 Trial for MR-141 Presbyopia Treatment

Fineline Cube Jun 27, 2025

US-based Viatris (NASDAQ: VTRS) announced positive topline results from the second pivotal Phase III VEGA-3...

Company Medical Device

Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study

Fineline Cube Jun 27, 2025

Ningbo-based structural heart disease device maker Jenscare Scientific Co., Ltd (HKG: 9877) announced positive 30-day...

Company Drug

Innovent Biologics’ Mazdutide Gets NMPA Nod for Weight Management

Fineline Cube Jun 27, 2025

China’s National Medical Products Administration (NMPA) has approved Innovent Biologics, Inc.’s (HKG: 1801) mazdutide (IBI362),...

Company Deals

Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development

Fineline Cube Jun 27, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing...

Policy / Regulatory

China Raises Subsidy for Basic Public Health Services, Targets Vulnerable Groups

Fineline Cube Jun 27, 2025

China’s National Health Commission (NHC) released the “Notice on Improving Basic Public Health Services in...

Posts pagination

1 … 165 166 167 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.